A more accurate test to identify those truly at risk of preterm labour
Results in 5 minutes
Improved patient management
✔ Excellent PPV & NPV1
✔ Results within 5 minutes
✔ Speculum not required
✔ Not contraindicated by intercourse, semen, urine or trace amounts of blood
✔ No digital reader required
✔ Wide gestational age usage – 20 weeks and 0 days to 36 weeks and 6 days
Enquire about PartoSure®
What is PartoSure®
The PartoSure® test is a rapid, qualitative test for detecting the presence of placental alpha microglobulin 1 (PAMG-1) in cervicovaginal secretions in pregnant women with signs and symptoms of early preterm labour.
How does it work?
The PartoSure® test detects the protein PAMG-1 . PAMG-1 is a placental protein found in high concentrations in the amniotic cavity. Due to the low concentration of PAMG-1 in normal vaginal discharge, studies have demonstrated a strong correlation between a positive PAMG-1 test and imminent delivery in patients presenting with threatened PTL and intact membranes2.
The importance of preterm labour diagnosis
Accurately assessing the risk of preterm birth is a difficult diagnosis with significant implications. Clinical evaluation alone is limited in its ability to predict imminent delivery among patients with signs of threatened preterm labour (PTL).
According to ACOG guidelines, traditional biomarker tests, such as those based on the detection of fetal fibronectin (fFN), are reported to have poor positive predictive values (PPV) for imminent delivery1. The increased chance of false positives, indicated by a lower PPV, can lead to unnecessary admissions and interventions.
- 28% of patients presenting with signs and symptoms of threatened preterm labour may be admitted to the hospital3.
- Studies show 7% to 20% of patients admitted deliver within 7 days4.
Reducing unnecessary interventions may lead to decreased costs
Published studies suggest a lower rate of false positive test results and associated higher PPVs, such as those seen with PartoSure®, may contribute to:
- Decreasing unnecessary admissions and acute interventions.
- Reducing the length of stay of high risk patients.
- Minimising unnecessary patient transfers.
The York Health Economic Consortium has undertaken an analysis of PartoSure® and alternate biomarkers to assess the overall cost effectiveness6. Each unnecessary preterm labour admission is associated with costs such as antenatal corticosteroids (£5.00), nefidipine tocolysis (£1.00), inpatient admissions (£1,325.00) and in-utero transfers (£965.00).
The average NHS maternity unit uses 300 preterm labour tests per annum. The use of a more accurate test could result in a significant reduction in false positive results. Below is a scenario-analysis produced by the York Health Economic Consortium. It is based on the following assumptions:
- The hospital is a non-tertiary centre and in-utero transfers are required.
- 300 tests are used per annum.
- PartoSure® is compared with fetal fibronectin 50ng/ml (Quick Check Test) and Actim Partus (IGFBP-1).
- 100% of patients are eligible for the PartoSure® test and 90% are eligible for the comparator tests, due to contraindications.
These results show that in a non-tertiary hospital with 300 patients presenting with symptoms of PTB per year, PartoSure® is cost saving when compared to both Actim Partus and fFN 50ng/ml tests, with savings of £114,929 and £100,687 respectively.
- Sold in boxes of 20 tests
- Store the PartoSure® test kit in a dry place at 4 to 25°C, do not freeze the test.
- The PartoSure® test strip should be used within four (4) hours after removing the test strip from the foil pouch.
- PartoSure® product code is TDT-1-20, available to purchase directly or through NHSSC.